CA2665141C - Composition comprising crustacean gastrolith components and its use - Google Patents

Composition comprising crustacean gastrolith components and its use Download PDF

Info

Publication number
CA2665141C
CA2665141C CA2665141A CA2665141A CA2665141C CA 2665141 C CA2665141 C CA 2665141C CA 2665141 A CA2665141 A CA 2665141A CA 2665141 A CA2665141 A CA 2665141A CA 2665141 C CA2665141 C CA 2665141C
Authority
CA
Canada
Prior art keywords
caco3
pharmaceutical formulation
chitin
organic matter
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2665141A
Other languages
English (en)
French (fr)
Other versions
CA2665141A1 (en
Inventor
Amir Sagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ben Gurion University of the Negev Research and Development Authority Ltd
Original Assignee
Ben Gurion University of the Negev Research and Development Authority Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben Gurion University of the Negev Research and Development Authority Ltd filed Critical Ben Gurion University of the Negev Research and Development Authority Ltd
Publication of CA2665141A1 publication Critical patent/CA2665141A1/en
Application granted granted Critical
Publication of CA2665141C publication Critical patent/CA2665141C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
CA2665141A 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components and its use Active CA2665141C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL178495 2006-10-05
IL178495A IL178495A (en) 2006-10-05 2006-10-05 Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
PCT/IL2007/001211 WO2008041236A2 (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components, calcium carbonate and its use

Publications (2)

Publication Number Publication Date
CA2665141A1 CA2665141A1 (en) 2008-04-10
CA2665141C true CA2665141C (en) 2015-03-24

Family

ID=39153987

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2665141A Active CA2665141C (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components and its use

Country Status (14)

Country Link
US (2) US20100098774A1 (enExample)
EP (1) EP2068891B1 (enExample)
JP (1) JP2010505818A (enExample)
CN (1) CN101563091A (enExample)
AU (1) AU2007303786B2 (enExample)
CA (1) CA2665141C (enExample)
CY (1) CY1114930T1 (enExample)
DK (1) DK2068891T3 (enExample)
ES (1) ES2439741T3 (enExample)
IL (1) IL178495A (enExample)
PL (1) PL2068891T3 (enExample)
PT (1) PT2068891E (enExample)
SI (1) SI2068891T1 (enExample)
WO (1) WO2008041236A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257750B2 (en) * 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
CN101969962B (zh) 2007-10-22 2014-10-22 艾玛菲克有限公司 包含磷酸化氨基酸、合成的磷酸化肽和胃石蛋白的稳定的无定形碳酸钙
CA3056570C (en) * 2011-12-13 2022-04-19 Amir Sagi Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
RU2637019C2 (ru) 2012-08-07 2017-11-29 Аморфикал Лтд. Способ получения стабилизированного аморфного карбоната кальция
CN105007925A (zh) * 2013-02-11 2015-10-28 艾玛菲克有限公司 用于加速骨生长的无定形碳酸钙
CN103417635B (zh) * 2013-08-15 2015-05-20 张荣惠 接骨药
RU2740453C2 (ru) 2014-07-31 2021-01-14 Аморфикал Лтд. Неводные жидкие и полутвердые составы аморфного карбоната кальция
US12121538B2 (en) 2015-06-04 2024-10-22 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
IL256065B2 (en) * 2015-06-04 2024-04-01 Amorphical Ltd Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates
BR122022001962B1 (pt) * 2015-12-14 2023-05-16 Société des Produits Nestlé S.A. Composição nutricional sintética, seu uso, e derivado de ácido graxo
US11478011B2 (en) 2015-12-14 2022-10-25 Societe Des Produits Nestle S.A. Nutritional compositions and infant formula for promoting de novo myealination
EP4233907A3 (en) * 2015-12-14 2024-01-10 Société des Produits Nestlé S.A. Nutritional compositions and infant formulas to promote myelination in the brain
AU2017210259B2 (en) 2016-01-18 2022-11-03 Amorphical Ltd. Stabilized amorphous calcium carbonate as a supplement for cell culture media
KR20250114395A (ko) 2016-01-18 2025-07-29 아모피컬 리미티드 신경, 근육 및 불임 질환 또는 병증의 치료를 위한 안정화된 무정형 탄산칼슘
CN114948992A (zh) * 2016-10-25 2022-08-30 艾玛菲克有限公司 用于治疗白血病的无定形碳酸钙
CA3144221A1 (en) 2019-07-23 2021-01-28 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237147A (en) 1974-01-04 1980-12-02 Monsanto Company Stabilized amorphous calcium carbonate
US4199496A (en) * 1974-09-05 1980-04-22 Johnson Edwin L Process for the recovery of chemicals from the shells of crustacea
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US20060165784A1 (en) * 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement
US20030077604A1 (en) * 2000-10-27 2003-04-24 Yongming Sun Compositions and methods relating to breast specific genes and proteins
JP2002205947A (ja) * 2000-12-11 2002-07-23 Chafflose Corporation 水虫治療薬
JP2005501845A (ja) * 2001-08-16 2005-01-20 メディカル リサーチ カウンシル キチン微小粒子およびそれらの医学的用途
JP2004081739A (ja) * 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
AU2003271016A1 (en) * 2003-09-17 2005-04-06 Bio-Wave Institute Of Suzhou Hi-Tech New District Corporation, Ltd. Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
WO2005115414A2 (en) * 2004-05-26 2005-12-08 Ben-Gurion University Of The Negev Research And Development Authority Orally-administrable compositions comprising stable amorphous calcium carbonate
AU2005296271A1 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes

Also Published As

Publication number Publication date
ES2439741T3 (es) 2014-01-24
US20130122117A1 (en) 2013-05-16
DK2068891T3 (da) 2014-01-13
IL178495A (en) 2014-12-31
CN101563091A (zh) 2009-10-21
PL2068891T3 (pl) 2014-03-31
US20100098774A1 (en) 2010-04-22
CA2665141A1 (en) 2008-04-10
CY1114930T1 (el) 2016-12-14
WO2008041236A3 (en) 2009-05-14
EP2068891B1 (en) 2013-09-25
EP2068891A2 (en) 2009-06-17
PT2068891E (pt) 2013-12-27
AU2007303786B2 (en) 2012-07-26
WO2008041236A2 (en) 2008-04-10
AU2007303786A1 (en) 2008-04-10
JP2010505818A (ja) 2010-02-25
IL178495A0 (en) 2007-02-11
SI2068891T1 (sl) 2014-02-28
US8728533B2 (en) 2014-05-20

Similar Documents

Publication Publication Date Title
CA2665141C (en) Composition comprising crustacean gastrolith components and its use
KR101497003B1 (ko) 인산염 흡착제
CN101559218B (zh) 一种具有增加骨密度功能的组合物
JP2003504384A (ja) クエン酸カリウムカルシウム組成物および製造方法
CN101513484A (zh) 一种预防和治疗骨质疏松的药物组合物及其制备方法
CN107349333A (zh) 具有增加骨密度功效的组合物及其制备方法和应用
EP1651191B1 (en) Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use
WO2019134534A1 (zh) 一种e-10-羟基-2-癸烯酸在制备防治骨质疏松症的药品或保健品中的应用
EP2944314B1 (en) Preparation for treating arthritis and arthrosis
JP3248170B2 (ja) コンドロイチン硫酸蛋白複合体含有食品
CN102000110A (zh) 一种用于预防或治疗骨和关节疾病的组合物及其制备方法
HU200933B (en) Process for producing pharmaceutical composition for profilacting and treating osteoporosis
CN110384241A (zh) 一组有助于骨健康的组合物及其制备方法
CN114366764A (zh) 一种提高人体免疫力，预防和/或治疗骨关节炎的组合物
CN100387244C (zh) 抗骨质疏松症组合物
CN106173614A (zh) 一种具有增加骨密度功能的组合物及其制备方法
CN103316021B (zh) 一种骨化三醇和含钙物组成的药物组合物及用途
WO2019160500A1 (en) Use of ferrous amino acid chelate to increase calcium absorption and bone mass, and to treat osteoporosis
CN117064912A (zh) 一种矿物离子组合物及其在制备对痛症具有治疗作用的产品中的应用
CN120616124A (zh) 一种具有补骨健骨作用的药食同源营养组合物及其制备方法及应用
CN102406177B (zh) 一种壮骨的保健品
CN101444552A (zh) 治疗骨质疏松的中药制剂
CN111109603A (zh) 一种具有补肾壮骨作用的食品配方及制备方法
CA2897809A1 (en) Method and composition for accelerated consolidation of bone fractures
HK1048922B (en) Potassium calcium citrate compositions and methods for production

Legal Events

Date Code Title Description
EEER Examination request